436 related articles for article (PubMed ID: 22622494)
1. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
Lea WB; Kwak ES; Luther JM; Fowler SM; Wang Z; Ma J; Fogo AB; Brown NJ
Kidney Int; 2009 May; 75(9):936-44. PubMed ID: 19225557
[TBL] [Abstract][Full Text] [Related]
3. Targeting activated mineralocorticoid receptor: Occam's razor revisited.
Brem AS
Kidney Int; 2012 Sep; 82(6):619-20. PubMed ID: 22935878
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
[TBL] [Abstract][Full Text] [Related]
5. Cooperative Role of Mineralocorticoid Receptor and Caveolin-1 in Regulating the Vascular Response to Low Nitric Oxide-High Angiotensin II-Induced Cardiovascular Injury.
Pojoga LH; Yao TM; Opsasnick LA; Siddiqui WT; Reslan OM; Adler GK; Williams GH; Khalil RA
J Pharmacol Exp Ther; 2015 Oct; 355(1):32-47. PubMed ID: 26183312
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Minas JN; Thorwald MA; Conte D; Vázquez-Medina JP; Nishiyama A; Ortiz RM
Clin Exp Pharmacol Physiol; 2015 Nov; 42(11):1178-88. PubMed ID: 26234762
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.
Whaley-Connell A; Habibi J; Wei Y; Gutweiler A; Jellison J; Wiedmeyer CE; Ferrario CM; Sowers JR
Am J Physiol Renal Physiol; 2009 May; 296(5):F1013-22. PubMed ID: 19261739
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.
Liu S; Xie Z; Daugherty A; Cassis LA; Pearson KJ; Gong MC; Guo Z
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1568-79. PubMed ID: 23661677
[TBL] [Abstract][Full Text] [Related]
9. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.
Lijnen PJ; Petrov VV
Methods Find Exp Clin Pharmacol; 2003 Sep; 25(7):541-64. PubMed ID: 14571285
[TBL] [Abstract][Full Text] [Related]
10. Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury.
Tsuji H; Wang W; Sunil J; Shimizu N; Yoshimura K; Uemura H; Peck AB; Khan SR
World J Urol; 2016 Jan; 34(1):89-95. PubMed ID: 25981400
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
[TBL] [Abstract][Full Text] [Related]
12. Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease.
Bovée DM; Uijl E; Severs D; Rubio-Beltrán E; van Veghel R; Maassen van den Brink A; Joles JA; Zietse R; Cuevas CA; Danser AHJ; Hoorn EJ
Am J Physiol Renal Physiol; 2021 Apr; 320(4):F654-F668. PubMed ID: 33586496
[TBL] [Abstract][Full Text] [Related]
13. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
Brown NJ
Nat Rev Nephrol; 2013 Aug; 9(8):459-69. PubMed ID: 23774812
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism.
Hattori T; Murase T; Iwase E; Takahashi K; Ohtake M; Tsuboi K; Ohtake M; Miyachi M; Murohara T; Nagata K
Nagoya J Med Sci; 2013 Feb; 75(1-2):81-92. PubMed ID: 23544271
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of T-type Ca
Thuesen AD; Finsen SH; Rasmussen LL; Andersen DC; Jensen BL; Hansen PBL
Am J Physiol Renal Physiol; 2019 Aug; 317(2):F254-F263. PubMed ID: 31042060
[TBL] [Abstract][Full Text] [Related]
16. Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.
Jeewandara TM; Ameer OZ; Boyd R; Wyse BF; Underwood CF; Phillips JK
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):353-60. PubMed ID: 25676668
[TBL] [Abstract][Full Text] [Related]
17. Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury.
Hattori T; Murase T; Sugiura Y; Nagasawa K; Takahashi K; Ohtake M; Ohtake M; Miyachi M; Murohara T; Nagata K
Hypertens Res; 2014 Feb; 37(2):125-33. PubMed ID: 24048492
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
[TBL] [Abstract][Full Text] [Related]
19. This is not Dr. Conn's aldosterone anymore.
Brown NJ
Trans Am Clin Climatol Assoc; 2011; 122():229-43. PubMed ID: 21686229
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor antagonism inhibits vein graft remodeling in mice.
Ehsan A; McGraw AP; Aronovitz MJ; Galayda C; Conte MS; Karas RH; Jaffe IZ
J Thorac Cardiovasc Surg; 2013 Jun; 145(6):1642-9, 1649.e1. PubMed ID: 22982037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
